The USFDA has recently approved the first chikungunya vaccine in the USA for individuals aged 18 years and above who are at risk of exposure to the chikungunya virus (CHIKV). The vaccine contains live, weakened CHIKV that may cause symptoms similar to chikungunya disease in the vaccine recipients. Clinical trials The vaccine's safety was determined in two clinical trials conducted on about 3,500 adults, while its effectiveness was evaluated in a study conducted on 362 adults.
In the efficacy study, participants developed neutralizing antibodies against CHIKV following chikungunya vaccination. The neutralizing antibodies generated in the participants were above the threshold (micro-plaque reduction neutralization test 50 [μPRNT50] titer of ≥150) obtained in an earlier study conducted on non-human primates. Dosage : Single dose intramuscular injection Adverse reactions : Injection site…
